Atossa Therapeutics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more
Atossa Therapeutics Inc (YAG2) - Net Assets
Latest net assets as of September 2025: €49.79 Million EUR
Based on the latest financial reports, Atossa Therapeutics Inc (YAG2) has net assets worth €49.79 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€58.01 Million) and total liabilities (€8.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €49.79 Million |
| % of Total Assets | 85.82% |
| Annual Growth Rate | 48.05% |
| 5-Year Change | 163.09% |
| 10-Year Change | N/A |
| Growth Volatility | 134.2 |
Atossa Therapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Atossa Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Atossa Therapeutics Inc (2016–2024)
The table below shows the annual net assets of Atossa Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €71.48 Million | -21.47% |
| 2023-12-31 | €91.02 Million | -22.84% |
| 2022-12-31 | €117.96 Million | -14.60% |
| 2021-12-31 | €138.14 Million | +408.45% |
| 2020-12-31 | €27.17 Million | +106.51% |
| 2019-12-31 | €13.16 Million | +49.41% |
| 2018-12-31 | €8.81 Million | +26.90% |
| 2017-12-31 | €6.94 Million | +124.04% |
| 2016-12-31 | €3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Atossa Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15448825200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €283.27 Million | 396.31% |
| Total Equity | €71.48 Million | 100.00% |
Atossa Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Atossa Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Openedges Tech Inc
KQ:394280
|
$88.46 Million |
|
Fenix Resources Limited
F:4ER
|
$88.47 Million |
|
THONBURI HEALTHCARE GRO-NVDR
BK:THG-R
|
$88.55 Million |
|
Park City Group Inc
F:PJ4A
|
$88.56 Million |
|
Cogelec SA
PA:ALLEC
|
$88.37 Million |
|
Hanover Bancorp Inc
NASDAQ:HNVR
|
$88.31 Million |
|
Nordhealth AS
OL:NORDH
|
$88.25 Million |
|
LuxUrban Hotels Inc. 13.00% Series A Cumulative Redeemable Preferred Stock
NASDAQ:LUXHP
|
$88.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atossa Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 91,016,000 to 71,477,000, a change of -19,539,000 (-21.5%).
- Net loss of 25,504,000 reduced equity.
- Other factors increased equity by 5,965,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-25.50 Million | -35.68% |
| Other Changes | €5.96 Million | +8.35% |
| Total Change | €- | -21.47% |
Book Value vs Market Value Analysis
This analysis compares Atossa Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.58x to 12.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.62 | €6.75 | x |
| 2018-12-31 | €1.51 | €6.75 | x |
| 2019-12-31 | €1.44 | €6.75 | x |
| 2020-12-31 | €0.57 | €6.75 | x |
| 2021-12-31 | €1.09 | €6.75 | x |
| 2022-12-31 | €0.93 | €6.75 | x |
| 2023-12-31 | €0.73 | €6.75 | x |
| 2024-12-31 | €0.55 | €6.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atossa Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-35.68%) is above the historical average (-83.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -205.64% | 0.00% | 0.00x | 1.34x | €-6.68 Million |
| 2017 | -117.06% | 0.00% | 0.00x | 1.18x | €-8.82 Million |
| 2018 | -129.53% | 0.00% | 0.00x | 1.33x | €-12.29 Million |
| 2019 | -131.04% | 0.00% | 0.00x | 1.10x | €-18.56 Million |
| 2020 | -65.62% | 0.00% | 0.00x | 1.58x | €-20.54 Million |
| 2021 | -14.92% | 0.00% | 0.00x | 1.02x | €-34.42 Million |
| 2022 | -22.85% | 0.00% | 0.00x | 1.05x | €-38.76 Million |
| 2023 | -33.06% | 0.00% | 0.00x | 1.06x | €-39.20 Million |
| 2024 | -35.68% | 0.00% | 0.00x | 1.07x | €-32.65 Million |
Industry Comparison
This section compares Atossa Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atossa Therapeutics Inc (YAG2) | €49.79 Million | -205.64% | 0.17x | $88.44 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |